Imfinzi plus FLOT chemotherapy significantly improves overall survival in resectable G/GEJ adenocarcinoma compared to placebo plus FLOT. The MATTERHORN trial showed consistent survival benefits across ...
MarketWatch: ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA(R) Plus CAR-NK, Chemo-Free Therapy
The MarketWatch News Department was not involved in the creation of this content. -- Primary endpoint of QUILT-3.078 is overall survival; median overall survival has not yet been reached, with 19 of ...
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA(R) Plus CAR-NK, Chemo-Free Therapy
Dr. Miranda Gogishvili, a medical oncologist at the High Technology Medical Center, University Clinic in Tbilisi, Georgia, said the six-year follow-up showed a median overall survival of 26 months ...
The American Journal of Managed Care: Drug Survival of Psoriasis Biologics Associated With Efficacy, Safety Profile
Drug survival rates of biologics in patients with psoriasis were shown to be associated with their effectiveness and safety profiles, in which incidence of psoriatic arthritis, nail involvement, and ...
The New England Journal of Medicine: Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer
ascopubs.org: Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer.
Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer.
MedPage Today: Recurrent Metastatic NSCLC vs De Novo Stage IV: How Do Survival Rates Compare?
Recurrent Metastatic NSCLC vs De Novo Stage IV: How Do Survival Rates Compare?
ascopubs.org: Genetic profile and survival outcomes in a modern cohort of patients with biliary tract cancers (BTC): Single center experience in New York City.